Laurie Toich, Assistant Editor

Under the new regulations, opioid prescriptions in Delaware may not exceed 1-week.

FDA approves nivolumab (Opdivo) injection for patients with advanced or metastatic urothelial carcinoma.

IMR-687 can reduce the sickling of red blood cells.

Opdivo approved as an intravenous treatment for urothelial carcinoma.

Keytruda previously granted breakthrough therapy designation as a second-line treatment for patients with bladder cancer.

Top news of the day from across the healthcare landscape.

Keytruda granted priority review as a first- and second- line treatment for bladder cancer.

Top articles of the week from The American Journal of Pharmacy Benefits.

Ocrelizumab may effectively treat patients with relapsing multiple sclerosis and primary progressive multiple sclerosis.

Researchers have found that depleting the environment of arginine plus a glutamine inhibitor may treat multiple types of cancer.

Cancer may be stopped by depriving cells of vital nutrients.

Repetitive transcranial magnet stimulation shows promise treating symptoms of MS.

Only 15% of primary care physicians support fully repealing the Affordable Care Act.

Working memory was improved in patients with MS who underwent repetitive transcranial magnetic stimulation.

A herpes candidate vaccine was observed to prevent genital lesions, and viral replication.

Patients diagnosed with hypertension over 80-years-old have a lower risk of developing dementia.

Some Medicare beneficiaries with cancer spent more than 60% of their annual income on out-of-pocket costs.

Metformin shown to alter metabolic pathways of cancer cells.

Squalamine was seen to inhibit α-synuclein and associated toxicities in models of Parkinson’s disease.

Construction and agriculture workers compose a majority of skin cancer deaths.

Overweight patients who experience an inflammatory response are at a higher risk for diabetes.

Top news of the day from across the healthcare landscape.

Approximately 52% of Americans want to keep or improve the Affordable Care Act.

Ocrelizumab reduced disease activity in patients with relapsing multiple sclerosis and primary progressive multiple sclerosis.

Rural Americans may be at an increased risk of death from heart disease, cancer, unintentional injuries, chronic lower respiratory disease, and stroke.

Ductal carcinoma in situ influences risk of all-cause mortality.

A combination of 3 treatments successfully treated a canine with aggressive oral melanoma.

Patient with ductal carcinoma in situ had a lower risk of all-cause mortality compared with the general population.

Top news of the day from across the healthcare landscape.